In a recent study, PKM2 was reported to regulate the transactivation of β-catenin in response to epidermal growth factor receptor (EGFR) activation [58] and was also suggested to play a critical role in mediating β-catenin nuclear localization in renal cell carcinoma treated with metformin. This evidence concerns the gene PKM and renal cell carcinoma.